CVS estimates GLP-1 costs balance out at $350-per-month net price

Advertisement

A GLP-1 net price of roughly $350 per month over three years would balance out pharmacy spending and observed medical savings, according to a Nov. 15 white paper from CVS Health.

The study relied on anonymized medical and pharmacy claims from Aetna’s commercial fully insured members. The report said the $350 monthly figure is an average across the study population based on internal modeling, not a single breakeven price that applies to every patient or indication. The study compared users and non-users over three years.

While GLP-1 use was linked to better clinical outcomes, as well as reduced hospital use and medical spending, the total cost of care remains elevated for GLP-1 users compared with similar non-users. The rise in pharmacy spending outpaced the drop in medical spending.

Medical spending for GLP-1 users was about $9,400 lower per member in the third year of follow-up than for similar non-users. However, net pharmacy spending was $13,300 steeper per member, leaving their total cost of care about $3,900 higher.

Hospitalization rates were 34% to 42% lower among GLP-1 initiators than matched non-users across the three years of follow-up. Emergency department visit rates were 10% to 12% lower in the first and second years. In the earlier-year analyses, those who initiated GLP-1s also had 14% lower odds of major adverse cardiovascular events.

Outcomes were generally better for adherent GLP-1 users, defined as those whose prescriptions covered at least 80% of days during the follow-up. By the third year, medical spending was $13,000 lower for adherent members, but incremental net pharmacy costs were up $20,300, compared to similar non-users. This resulted in a $7,300 net increase in total cost of care.

CVS said getting more value from GLP-1s requires treating the patients most likely to benefit, helping them stay on therapy and working toward sustainable pricing.

Advertisement

Next Up in GLP-1s

Advertisement